The bear case for EVGN is also similar to many drug discovery and development biotech companies.
That is, when will the research efforts be monitized in terms of either a drug on the market (or at least showing solid efficacy in PH2 or Ph3 trials) or when the plant biotech product will show significant commercial sales (or trial results sufficient to boast).
Market Data 
Markets 
AI
